Ardelyx (ARDX) Consolidated Net Income (2013 - 2026)
Ardelyx posted quarterly Consolidated Net Income of -$37.6 million for Q1 2026, up 8.6% year-on-year from -$34.6 million in Q1 2025, and down 9139.56% on a QoQ basis from -$407000.0 in Q4 2025.
Ardelyx (ARDX) has 14 years of Consolidated Net Income data on file, last reported at -$37.6 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income rose 8.6% year-over-year to -$37.6 million; the trailing twelve-month figure through Mar 2026 stood at -$58.1 million (down 7.99% YoY), and the FY2025 full-year result was -$61.6 million, down 57.4% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$37.6 million, down from -$407000.0 in the prior quarter.
- Across five years, Consolidated Net Income topped out at $10.7 million in Q4 2022 and bottomed at -$41.1 million in Q1 2025.
- The 5-year median for Consolidated Net Income is -$19.1 million (2025), against an average of -$16.0 million.
- The widest annual swing landed in 2022, when Consolidated Net Income jumped 129.52%; it then sank 369.3% in 2023.
- A 5-year view of Consolidated Net Income shows it stood at $10.7 million in 2022, then plunged by 369.3% to -$28.8 million in 2023, then jumped by 116.13% to $4.6 million in 2024, then sank by 108.76% to -$407000.0 in 2025, then sank by 9139.56% to -$37.6 million in 2026.
- The last three Consolidated Net Income figures came in at -$37.6 million (Q1 2026), -$407000.0 (Q4 2025), and -$969000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Ardelyx | 1.48 Bn | 1.25 Bn | 89.66 Mn | -37.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.61 Mn |
| Dec 31, 2025 | -407,000.00 |
| Sep 30, 2025 | -969,000.00 |
| Jun 30, 2025 | -19.08 Mn |
| Mar 31, 2025 | -41.14 Mn |
| Dec 31, 2024 | 4.65 Mn |
| Sep 30, 2024 | -809,000.00 |
| Jun 30, 2024 | -16.45 Mn |
| Mar 31, 2024 | -26.52 Mn |
| Dec 31, 2023 | -28.80 Mn |
| Sep 30, 2023 | 6.63 Mn |
| Jun 30, 2023 | -17.12 Mn |
| Mar 31, 2023 | -26.77 Mn |
| Dec 31, 2022 | 10.70 Mn |
| Sep 30, 2022 | -22.89 Mn |
| Jun 30, 2022 | -26.94 Mn |
| Mar 31, 2022 | -28.07 Mn |
| Dec 31, 2021 | -36.23 Mn |
| Sep 30, 2021 | -43.59 Mn |
| Jun 30, 2021 | -45.19 Mn |
| Mar 31, 2021 | -33.16 Mn |
| Dec 31, 2020 | -28.88 Mn |
| Sep 30, 2020 | -18.11 Mn |
| Jun 30, 2020 | -24.96 Mn |
| Mar 31, 2020 | -22.37 Mn |
| Dec 31, 2019 | -19.79 Mn |
| Sep 30, 2019 | -23.54 Mn |
| Jun 30, 2019 | -25.47 Mn |
| Mar 31, 2019 | -26.14 Mn |
| Dec 31, 2018 | -27.86 Mn |
| Sep 30, 2018 | -24.13 Mn |
| Jun 30, 2018 | -22.29 Mn |
| Mar 31, 2018 | -17.02 Mn |
| Dec 31, 2017 | 10.08 Mn |
| Sep 30, 2017 | -20.72 Mn |
| Jun 30, 2017 | -25.72 Mn |
| Mar 31, 2017 | -28.01 Mn |
| Dec 31, 2016 | -32.07 Mn |
| Sep 30, 2016 | -29.03 Mn |
| Jun 30, 2016 | -28.61 Mn |
| Mar 31, 2016 | -23.47 Mn |
| Dec 31, 2015 | -17.00 Mn |
| Sep 30, 2015 | -18.13 Mn |
| Jun 30, 2015 | 9.01 Mn |
| Mar 31, 2015 | -3.50 Mn |
| Dec 31, 2014 | -3.90 Mn |
| Sep 30, 2014 | 74,000.00 |
| Jun 30, 2014 | 3.75 Mn |
| Mar 31, 2014 | -3.07 Mn |
| Dec 31, 2013 | -4.27 Mn |
| Sep 30, 2013 | -934,000.00 |
| Jun 30, 2013 | -891,000.00 |